Protenus Granted Seventh Patent for Drug Diversion Surveillance Technology

New patent granted assists hospitals with greater coverage to support drug waste events

BALTIMORE, MD, July 18, 2024  - Protenus, provider of the leading healthcare compliance analytics platform, today announced a new grant of a U.S. Patent that supports its ongoing efforts to deliver drug diversion surveillance technology that enables hospitals and health systems to be more efficient and proactively eliminate risk to their organization and patients. 

The new grant of U.S. Patent No. 12,033,736 is titled “Methods and Systems for Analyzing Accessing of Drug Dispensing Systems.”  With this patent, Protenus now holds seven granted U.S. patents covering various techniques for detecting anomalous drug dispensing events.  The newly-granted patent covers the usage of rules or patterns for determining when a drug wasting event is a misappropriation event. The patent further describes modifying the rules or patterns for detecting possible subsequent misappropriation events.

“Policies and prevention tactics alone will not eliminate the diversion or misappropriation of controlled substance waste. Waste disposal should be audited, especially in high-use and complex care settings,”  states Nick Culbertson, CEO and Co-Founder of Protenus. 

He continues, “Our award winning drug diversion surveillance solution is designed to review drug handling patterns by monitoring 100% of medication handling transactions, bringing suspicious or likely events to the attention of the health system’s investigator for further review. This new patent reflects our continued commitment to supporting the complex intricacies of our customers’ diversion monitoring strategies.”

Protenus holds more than a dozen granted U.S. patents covering various key aspects of patient privacy monitoring and drug diversion surveillance technologies, along with several other pending U.S. and foreign patent applications.

Any licensing inquiries or other questions about the Protenus patent portfolio should be directed to Amy Much, Protenus's General Counsel, at amy.much@protenus.com.

About Protenus

Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. Founded in 2014, Protenus was awarded Best in KLAS for both patient privacy monitoring and drug diversion surveillance solutions two years in a row (2023-2024), is a three-time winner of Forbes’ America’s Best Startup Employers, is a Great Place to Work®-Certified company, was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on X (Twitter) @Protenus.

Media Contact

Michelle Del Guercio
Chief Marketing Officer
michelle.delguercio@protenus.com